148 related articles for article (PubMed ID: 11845103)
1. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
Marques-Vidal P; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
[TBL] [Abstract][Full Text] [Related]
2. [Medical cost of cardiovascular risk factors prevention in France].
Marques-Vidal P; Bongard V; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
Arch Mal Coeur Vaiss; 2002 Apr; 95(4):275-81. PubMed ID: 12055766
[TBL] [Abstract][Full Text] [Related]
3. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city.
Tang JL; Wang WZ; An JG; Hu YH; Cheng SH; Griffiths S
Int J Epidemiol; 2010 Feb; 39(1):244-54. PubMed ID: 19491141
[TBL] [Abstract][Full Text] [Related]
4. Influence of parental histories of cardiovascular risk factors on risk factor clusters in the offspring.
Lascaux-Lefebvre V; Ruidavets JB; Arveiler D; Amouyel P; Haas B; Cottel D; Bingham A; Ducimetière P; Ferrières J
Diabetes Metab; 2001 Sep; 27(4 Pt 1):503-9. PubMed ID: 11547225
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
Journath G; Hellénius ML; Petersson U; Theobald H; Nilsson PM;
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
[TBL] [Abstract][Full Text] [Related]
6. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
[TBL] [Abstract][Full Text] [Related]
8. Education, socioeconomic and lifestyle factors, and risk of coronary heart disease: the PRIME Study.
Yarnell J; Yu S; McCrum E; Arveiler D; Hass B; Dallongeville J; Montaye M; Amouyel P; Ferrières J; Ruidavets JB; Evans A; Bingham A; Ducimetière P;
Int J Epidemiol; 2005 Apr; 34(2):268-75. PubMed ID: 15319403
[TBL] [Abstract][Full Text] [Related]
9. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
[TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
Portolés J; López-Gómez JM; Aljama P
Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
Marshall T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
[TBL] [Abstract][Full Text] [Related]
12. Cost of renal transplant maintenance immunosuppression: effect of control of vascular risk factors.
Gentil MA; López M; González-Roncero F; Cantarell C; Marco J
Transplant Proc; 2005 Apr; 37(3):1464-5. PubMed ID: 15866640
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
15. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
17. [Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002].
Girerd X; Mourad JJ; Vaïsse B; Poncelet P; Mallion JM; Herpin D
Arch Mal Coeur Vaiss; 2003; 96(7-8):750-3. PubMed ID: 12945216
[TBL] [Abstract][Full Text] [Related]
18. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
20. The cost of treating high blood pressure in general practice in France.
Tibi-Levy Y; de Pouvourville G; Westerloppe J; Bamberger M
Eur J Health Econ; 2008 Aug; 9(3):229-36. PubMed ID: 17566802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
